| Drug | Drug classification | Fibrotic disease model | Mechanism of fibrosis inhibiton | Animal type/Reference |
| Tunicamycin | ERS inducer | Hepatic fibrosis | Induce HSCs apoptosis | Rat [ |
| ALLN | Cysteine protease inhibitors | Hepatic fibrosis | Induce HSCs necrosis | Rat [ |
| MDL28170 | Cysteine protease inhibitors | Myocardial fibrosis | Disassembles cell-cell adhesion at intercalated discs by degrading N-cadherin | Mice [ |
| Calpeptin | Cysteine protease inhibitors | Myocardial fibrosis | Inhibition of cardiac parenchymal cell apoptosis | Mice [ |
| Calpeptin | Cysteine protease inhibitors | Pulmonary fibrosis | Decreased IL-6 dependent cell proliferation and angiopoietin-1 dependent cell migration | Mice [ |
| Calpeptin | Cysteine protease inhibitors | Pulmonary fibrosis | Reverse TGFβ1-Smad2/3 mediated EMT | Mice [ |
| MDL28170 | Cysteine protease inhibitors | Pulmonary vascular fibrosis | Inhibition of HIF-1α signaling pathway | Mice [ |
| MDL28170 | Cysteine protease inhibitors | Pulmonary vascular fibrosis | Inhibition of PI3K/AKT-mediated EMT | Mice [ |
| PD150606 | Cysteine protease inhibitors | SSc-ILD pulmonary fibrosis | Inhibition of macrophage M1 polarizatio | Mice [ |
| ALLN | Cysteine protease inhibitors | SSc-ILD pulmonary fibrosis | Inhibition of TGFβ1/Smad2/3 mediated EMT | Mice [ |
